Skip to search formSkip to main contentSkip to account menu

SNAR-A13 gene

Known as: SNAR-A13, small ILF3/NF90-associated RNA A13, snaR-A53139991 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice
SummaryThe goals of the present study were to define the anticancer activity of LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2,5… 
2018
2018
Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus
Background X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by Bruton’s tyrosine kinase (BTK) mutation… 
2015
2015
Human rhinovirus serotypes in the nasal washes and mucosa of patients with chronic rhinosinusitis
Chronic rhinosinusitis (CRS) can be aggravated by viral upper respiratory infections. We aimed to investigate whether any… 
2014
2014
Macrophage-Activating Lipopeptide-2 Requires Mal and PI3K for Efficient Induction of Heme Oxygenase-1
Aims This study is to investigate the mechanisms by which macrophage-activating lipopeptide-2 (MALP-2) induces heme oxygenase (HO… 
2010
2010
Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may… 
Highly Cited
2007
Highly Cited
2007
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
2007
2007
Chemosensitizing Anti-Cancer Activity of LFM-A13, a Leflunomide Metabolite Analog Targeting Polo-like Kinases
LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide) has recently been identified as an inhibitor of Polo-like… 
2007
2007
Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
The leflunomide (CAS 75706-12-6) metabolite (LFM) analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide… 
1986
1986
Purification and properties of lumazine proteins from Photobacterium strains.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)